Use of glycogen phosphorylase BB measurement with POCT in the diagnosis of acute coronary syndromes. A comparison with the ELISA method.

Background: Glycogen Phosphorylase BB (GPBB) is considered an early and specific marker of myocardial necrosis and ischemia. A POCT kit GPBB for diagnostic use has recently been approved.

Aim: an evaluation of the correspondence of qualitative POCT GBPP measurements with ELISA test results.

Urinary clusterin concentrations--a possible marker of nephropathy? Pilot study.

Background: Clusterin is a glycoprotein which participates in a number of pathophysiological processes in the organism. Information about clusterin use in the diagnosis of nephropathy and the differential diagnosis of proteinuria has been published recently.

Aim: Search for correlations between urinary clusterin concentration and other renal function markers.

Urine fetuin-A values in relation to the presence of urolithiasis.

Objective: To investigate the relationship of urine fetuin-A and other promotors and inhibitors of urine crystalization with urolithiasis, as fetuin-A inhibits the precipitation of hydroxyapatite from supersaturated solutions of calcium and phosphate in vitro but no information on urine fetuin-A in patients with urolithiasis is available.

Patients And Methods: In all, 39 patients with urolithiasis and 22 individuals with no urolithiasis or probands with undetected stones were involved. All patients underwent kidney ultrasonography and X-ray examination, and body mass index (BMI) was calculated.

Angiopoietin-like protein 3: development, analytical characterization, and clinical testing of a new ELISA.

The aim of our work was to develop an assay for the determination of angiopoietin-like protein 3 (Angptl3) in human blood, and investigate its levels in healthy volunteers and donors suffer from metabolic syndrome and familiar hypercholesterolemia. We developed and evaluated the sandwich ELISA method for the quantitative determination of human Angptl3 in serum samples. We conducted also the pilot study on individuals with metabolic syndrome or familiar hypercholesterolemia and healthy probands.

Proguanylin: development, analytical characterization, and clinical testing of a new ELISA.

The aim of our work was to develop an assay for the determination of proguanylin in human blood, and investigate its levels in healthy volunteers and donors suffer from hypertension often accompanied by body sodium accumulation and plasma volume expansion. We developed and evaluated the sandwich ELISA method for the quantitative determination of human proguanylin in serum samples. We conducted also the pilot study on individuals with hypertension and oh healthy probands and measured proguanylin serum levels, serum and urine sodium and creatinine levels.